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ABSTRACT
Objectives: Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is mainly transmitted through respiration and 
direct contact. The status of the infection in the female genital system is still unknown. The study aimed to evaluate whether 
SARS-CoV-2 is present in the vaginal fluid of women with COVID-19 infection in reproductive period. 
Material and methods: Women who were between the ages of 18–50 years and clinically confirmed to have COVID-19 in-
fection at our hospital between 20 April–31 May 2020 were included in the study. Women who were in their menstrual 
cycle during the study and who had a known cervical intraepithelial lesion and/or cancer, sexually transmitted disease and 
history and/or symptoms of vaginitis were excluded from the study. In patients in whom no pathology was detected during 
the examination, a sample was taken from the vaginal fluid for PCR by using Dacron tip swab. Analysis was performed with 
Genesig Real-Time PCR COVID-19 kit (Primer Design, England). 
Results: Eighteen women who were in reproductive period and diagnosed with severe COVID-19 pneumonia were in-
cluded in the study. The mean age of the patients was 38.16 ± 8.54. None of the patients were in their menopause period.  
The clinical symptoms of these women were similar to those of confirmed severe COVID-19 cases. SARS-CoV-2 was found 
to be negative in the samples taken from the vaginal fluid in all patients. 
Conclusions: SARS-CoV-2 virus was not detected in the vaginal fluid of the patients who tested positive for COVID-19 in 
reproductive period. 
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INTRODUCTION
Viral pneumonia and severe acute respiratory symptom 
observed in coronavirus disease (COVID-19) have spread 
between many countries in a short period of time and has 
affected the whole world, causing a pandemic to be de-
clared. Severe Acute Respiratory Syndrome Coronavirus 
2 (SARS-CoV-2), which is the pathogen of the coronavi-
rus disease, is a highly contagious virus, and it is mainly 
transmitted through the respiratory droplets of people 
in the immediate vicinity and through direct contact [1]. 
The virus especially affects the upper and lower respira-
tory systems in human body. It can lead to fever, cough, 
chest pain, dyspnea, fatigue, and muscle pains [2]. In ad-
dition, it has also been known to cause abdominal pain 
and diarrhea by affecting the gastrointestinal system, which 
can lead to acute cardiac destruction, arrhythmia and shock 
symptoms in the cardiovascular system, as well as men-
tal fog and confusion in the central nervous system, and 
patients facing mortality resulting from multiple organ fail-
ure [3]. However, it is still not clearly determined whether 
it creates infection in the female genital system. There are 
few studies conducted in the literature on the presence of 
SARS-CoV-2 virus in body fluids. It has been observed that 
very few women in post-menopausal period were included 
in the studies investigating the virus in the vaginal fluid [4]. 
Objectives
Determining this virus in the genital systems of women 
during the reproductive period is important in that it may 
help reporting especially the risk of transmission through 
sexual intercourse and from mother to baby during deliv-
ery. The purpose of the study was to investigate whether 
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there are SARS-CoV-2 virus symptoms in the vaginal 
fluids of women who are sexually active and in the repro-
ductive period. 
MATERIAL AND METHODS
Study group and ethical approval
In this cross-sectional prospective study, sexually ac-
tive menstruating women between the ages of 18–50 years 
who were hospitalized in the COVID-19 services of Sakarya 
University Training and Research Hospital, which was trans-
formed into a pandemic hospital where COVID-19 patients 
were treated and followed up, in Sakarya Province of Turkey. 
Patients who were clinically confirmed to have COVID-19 in-
fection (whose swap sample taken from the throat tested 
positive in PCR test) between 20 April–31 May 2020 were 
included in the study. Patients who were in their menstrual 
cycle during the study, who had a diagnosed cervical intraep-
ithelial lesion and/or cancer, sexually transmitted disease, 
and vaginitis history and symptoms were excluded from the 
study. All patients were informed about the study, and after 
obtaining their verbal/written approval, they were evaluated 
in lithotomy position. Ethical approval for the study was 
taken from Sakarya University Medical Faculty Ethical Com-
mittee (Project ID:16214662/050.01.04/83) (April 13, 2020).
Taking sample from the vaginal fluid
Within 0–2 days of hospitalization, samples were taken 
from the vaginal fluids for PCR test by using Dacron (Poly-
ester) tip swab from patients in whom no pathology was 
observed in the examination made after insertion of vaginal 
speculum in lithotomy position on the examination table. 
The swab sample was taken from the vaginal fluid by ap-
plying the swab on the anterior, posterior and lateral walls 
once, and touching the posterior fornix once. All samples 
taken were placed into screw-capped sealed vessels which 
contained 3 mL of viral transport medium. All samples were 
kept at 2–8°C in refrigerator right after taking the samples 
and were transported quickly to the laboratory. The samples 
were sent to the laboratory by complying with infection 
protection and control procedures and cold chain rules in 
triple transportation system. 
Nucleic acid isolation and Reverse Transcriptase 
Polymerase Chain Reaction (RT-PCR)
After the samples were accepted at the microbiology 
laboratory, all samples were studied in biosecurity cabin in 
level 3 negative pressure room. 
After the vaginal fluid samples were well vortexed, 
400 µL was removed and loaded onto BioRobot EZ1 (Qia-
gen, Germany) device, and 60 µL elution was taken. Total 
nucleic acid isolation was performed with EZ1 Virus Mini Kit 
v2.0 (Qiagen, Germany) in accordance with the company’s 
recommendations.  
For RT-PCR study, a total mixture with a volume of 20 µL 
made up of 10 µL master mix, 2 µL primary, and 8 µL RNA 
template was formed, and reaction was realized with a total 
of 20 µL reaction volume in the durations and at the tem-
peratures given in Table 1. 
At the end of the reaction, the curves whose Cycle 
Threshold (CT) value was lower than 45 and were ob-
served to be sigmoidal were interpreted as positive for 
SARS-CoV-2 RNA. 
RESULTS
Eighteen women in reproductive period with se-
vere COVID-19 pneumonia were included in the study. 
The mean age of the patients was 38.16 ± 8.54. None of the 
patients were in their menstrual cycle. The clinical symptoms 
of these patients were comparable to those of confirmed 
COVID-19 patients. The most common symptoms were fever 
(100% n = 18) and cough (66.6% n = 12). Other symptoms 
included sore throat (44.4% n = 8), fatigue (27.7% n = 5), 
and diarrhea (16.7% n = 3). Two patients complained of 
dyspnea, and no patients complained about urinary tract 
symptoms. While no chronic diseases were observed in the 
patients, hypertension (n = 5) and diabetes (n = 1) were 
present in some patients. Computer tomography scans of 
the patents were observed to be consistent with typical 
viral pneumonia. The swab samples taken from the throats 
of the patients at the time of hospitalization tested positive 
in PCR. PCR tests of these patients repeated after 24 hours 
also tested positive. ICU treatment was not required for 
any of the patients. For all patients, treatment with antiviral 
(oseltamivir/favipiravir) and antibacterial (azithromycin and 
hydroxychloroquine) drugs were initiated. Baseline char-
acteristics of the 18 patients infected with SARS-CoV-2 are 
presented in Table 2. The samples taken from the vaginal 
fluid tested negative for SARS-CoV-2 in all patients. 
DISCUSSION
In our study, viral RNA was not determined in the vaginal 
fluids of the COVID-19 positive women during the reproduc-
tive period with a mean age of 38.16 ± 8.54. The virus was 
Table 1. COVID-19 RT-PCR temperature and duration adjustments
Stages Temperature Duration
Reverse transcription 55°C 10 minutes
Enzyme activation 95°C 2 minutes
X50 Cycle
Denaturation 95°C 10 seconds
Binding and Stretching 60°C 60 seconds
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not detected in the vaginal fluid in the studies conducted 
on this issue in the literature as well. What makes our study 
different is that the patients included in the study were 
younger and in the reproductive period. In a similar study in 
which 12 pregnant women with a mean age of 32 ± 7.9 were 
included, the virus could not be shown in the vagina through 
isolation methods [5].
In a study carried out by Qui et al. [4], SARS-CoV-2 was 
investigated with PCR in the vaginal fluid samples of 10 pa-
tients aged between 50–80 in their postmenopausal pe-
riod who tested positive for COVID-19, and no virus was 
found. Moreover, in a study in which 35 patients, 28 of 
whom were in the postmenopausal period, were included, 
SARS-CoV-2 similarly could not be detected in the vaginal 
fluids [6]. According to International Menopause Society 
(IMS), it has been reported that within 4–5 years follow-
ing menopause, urogenital atrophy and vaginal dryness 
develop in most women [7]. Atrophy and dryness that 
develop in the vaginal epithelium as a result of hormonal 
changes in menopause may have caused lack of material, 
and PCR test results may have proved negative in these 
studies. 
SAR-CoV-2 is an enveloped RNA virus. It has been 
demonstrated that SARS-CoV-2 enters the body by bind-
ing to angiotensin-converting enzyme 2 receptors (ACE2) 
expressed in vascular endothelial membrane in many 
organs such as lungs, gastrointestinal system, kidney and 
testicles by spike proteins, and causes infection [8]. These 
ACE2 receptors have been shown to be non-existing in 
the vaginal epithelium [9]. This could be the reason why 
neither our study nor other studies could detect the virus 
in the vagina. 
The potential for a patient to spread the infection re-
quires the virus to be present in different body fluids. In 
the literature, the virus has been isolated in the urine, feces, 
nasopharyngeal swab sample and blood [10]. In a study 
conducted, it has been shown that although the clinical 
symptoms of the patents improved and PCR tested negative 
for the swab sample taken from the throat, the virus was 
found to be present in the samples taken in later periods and 
to continue spreading [11]. In our study, the samples were 
taken in early period and the virus could not be isolated in 
the vaginal fluid. Accordingly, since the invasion duration 
of the virus in the tissues is not known, the presence of 
the virus should be evaluated by taking samples from the 
vaginal fluid in later periods. 
The limitations of our study are that the number of 
patients included in the study was low, the patients were 
not evaluated together with their sexual partners, the pa-
tients did not have serious diseases that required intensive 
care though they tested positive in PCR, and the vaginal 
fluid samples were taken in the first days of hospitalization 
(0–2 days) at the beginning of the treatment. There is a need 
for further studies in which vaginal samples taken in later 
periods from women who were clinically confirmed to be 
infected with COVID-19 through PCR are compared. 
CONCLUSIONS
In our study, SARS-CoV-2 virus could not be detected 
in the vaginal fluids of female patients during the repro-
ductive period who tested positive for COVID-19 infection. 
Our results are important in that they show that the lower 
genital system in infected women in reproductive period is 
not a mode of transmission for SAR-CoV-2. In addition, our 
results can provide a guidance for the choice of delivery 
method in infected pregnant women in the management 
of SARS-CoV-2. Randomized controlled studies with large 
samples are needed regarding this issue. 
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